17:37 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

GSK, MorphoSys RA therapy misses in Phase IIb

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said GSK3196165 (formerly MOR103) plus methotrexate missed the primary endpoint in the Phase IIb BAROQUE trial to treat moderate to severe rheumatoid arthritis in patients who had an inadequate response to...
21:15 , Oct 22, 2018 |  BC Extra  |  Clinical News

GSK, MorphoSys RA therapy misses in Phase IIb

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said GSK3196165 (formerly MOR103) plus methotrexate missed the primary endpoint in the Phase IIb BAROQUE trial to treat moderate to severe rheumatoid arthritis in patients who had an inadequate response to...
15:35 , Jul 27, 2018 |  BC Week In Review  |  Company News

GSK, 23andMe partner on target, drug discovery

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on July 25, when the pharma provided an R&D update, announced 2Q18...
23:14 , Jul 25, 2018 |  BC Extra  |  Company News

GSK's near-term R&D prospects include an ADC as it pivots to immunology

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on Wednesday, when the pharma provided an R&D update, announced 2Q18 earnings...
21:41 , Nov 30, 2017 |  BC Innovations  |  Strategy

Doctors in the house

While academic partnerships have become par for the course in pharma, GSK is going a step beyond the standard model of external alliances by bringing professors in-house with virtually unrestricted access to its activities. The...
07:00 , Apr 25, 2016 |  BC Week In Review  |  Clinical News

Subcutaneous GSK3196165: Phase II started

GlaxoSmithKline began a double-blind, placebo-controlled, European Phase II trial to evaluate 8 injections of subcutaneous GSK3196165 over 12 weeks in 40 patients. GSK has exclusive, worldwide rights to the compound from MorphoSys (see BioCentury, June...
07:00 , Aug 4, 2014 |  BioCentury  |  Finance

Voucher leapfrog

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are hoping to use a newly acquired Priority Review voucher to jump ahead of Amgen Inc. (NASDAQ:AMGN) in the race to be first to market with a...
01:10 , Mar 1, 2014 |  BC Extra  |  Financial News

MorphoSys expects 2014 revenues below 2013

Antibody company MorphoSys AG (Xetra:MOR; Pink:MPSYF) swung to a loss in 4Q13 and said it expects 2014 revenues to be below 2013 figures. The company's 2013 revenues of EUR 78 million ($107.3 million) were up...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Company News

MorphoSys, GlaxoSmithKline deal

MorphoSys granted GlaxoSmithKline exclusive, worldwide rights to develop and commercialize its MOR103 program. MorphoSys will receive €22.5 million ($29.3 million) up front and is eligible for up to €423 million ($549.9 million) in milestones, plus...
07:00 , Jun 10, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) gained $0.24 to $19.79 on Friday after partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) submitted a Type II variation application to EMA to expand the European label of Rienso ferumoxytol...